A Potential New Option for Targeted Treatment of Pancreatic Cancer is on the Horizon
Systemic (intravenous) chemotherapy is considered the standard of care for pancreatic cancer. This approach to treatment is often associated with debilitating side effects and may be ineffective in treating this type of cancer due to pancreatic tumors lacking blood vessels (“Tumor Feeders”). These blood vessels are critical for transporting systemic administration of chemotherapy to the tumor. Tumor feeders are critical for transporting systemic administration of chemotherapy to the tumor.
The Phase 3 TIGeR-PaC clinical trial is a randomized multi-center study using RenovoRx’s innovative therapy platform, RenovoTAMP® (RenovoRx Trans-arterial Micro-perfusion), to evaluate RenovoRx’s first product candidate, RenovoGem, to treat locally advanced pancreatic cancer (LAPC) through the intra-arterial delivery of gemcitabine (an FDA-approved chemotherapy). The study has a primary endpoint of overall survival and several secondary endpoints, including quality of life.
Based on the results of Phase 1/2 and observational registry studies, intra-arterial delivery of chemotherapy via RenovoTAMP, which targets delivery of treatment in proximity to the tumor and pancreatic tissue, reduced tolerability issues associated with systemic chemotherapy and demonstrated improved patient survival.
TIGeR-PaC is currently enrolling locally advanced, unresectable LAPC patients at multiple clinical centers across the U.S. Find a clinical site.